FIXX Profile
Homology Medicines Inc. (FIXX) is a genetic medicines company that develops gene therapies and gene editing treatments for patients with rare genetic diseases. The company's proprietary platform technology, called the HMI-102 vector system, enables precise and efficient insertion of corrective genes into a patient's DNA.
Homology's lead product candidate is HMI-102, which is in clinical development for the treatment of phenylketonuria (PKU), a rare metabolic disorder caused by a deficiency of an enzyme called phenylalanine hydroxylase. Homology also has preclinical programs for the treatment of other rare genetic diseases, including Hurler syndrome, Fabry disease, and metachromatic leukodystrophy.
The company has partnerships with Novartis, which is developing gene therapies using Homology's technology, and with Beam Therapeutics, a gene editing company. Homology also has collaborations with academic institutions and non-profit organizations to advance research in gene therapy and gene editing.
As of September 30, 2021, Homology had $211.7 million in cash, cash equivalents, and marketable securities. The company's stock is listed on the Nasdaq Global Market under the ticker symbol "FIXX."
|
